publication date: Apr. 14, 2017
Drugs and Targets FDA removes restrictions on use of erythropoiesis-stimulating agents
FDA has removed the Risk Evaluation and Mitigation Strategy requirements for erythropoiesis-stimulating agents in patients with anemia due to associated myelo-suppressive chemotherapy.
The text of the FDA announcement follows:
Epoetin alfa and darbepoetin alfa are erythropoiesis-stimulating agents, approved for the treatment of anemia resulting from chronic kidney disease, chemotherapy, certain treatments for Human Immunodeficiency Virus, and also to reduce the number of blood transfusions during and after certain major surgeries.
ESAs work like the human protein erythropoietin, which stimulates bone marrow to make red blood cells. Epoetin alfa (marketed as Procrit and Epogen) and darbepoetin alfa (marketed as Aranesp), are manufactured by Amgen Inc.
In 2017, the FDA determined that the REMS, which was limited to the use of Epogen/Procrit and Aranesp to treat patients with anemia due to associated myelosuppressive chemotherapy is no longer necessary to ensure that the benefits of Epogen/Procrit and Aranesp outweigh its risks of shortened overall survival and/or increased risk of tumor progression or recurrence in patients with cancer.
The FDA made this determination based on an evaluation of the results of the REMS Assessments submitted by Amgen Inc., and additional FDA analyses to understand the impact of the various regulatory and other actions on the use of ESAs. … Continue reading FDA removes restrictions on use of erythropoiesis-stimulating agents
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.